The past decade has witnessed the great benefit of the personalized drug therapy in the treatment of non-small-cell lung cancers (NSCLC) [1]–[3], which was designed to target different drug targets, such as KRAS [4], EGFR [5], EML4-ALK [6], the newly found CD74-ROS1 [7], [8], etc. Crizotinib, the latest launched NSCLC drug, was originally designed to competitively inhibit the activity of c-MET [9], whereas has been approved by U.S. Food and Drug Administration (FDA) for the treatment of advanced NSCLC with anaplastic lymphoma kinase (ALK) rearrangements in 2011. This evidence concerns the gene CD74 and non-small cell lung carcinoma.